文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

人工智能心电图与超声心动图追踪转甲状腺素蛋白淀粉样心肌病临床前进展

Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy.
PubMed 文献 · Eur Heart J · 2025-01-01

该回顾性研究在耶鲁纽黑文健康系统(YNHHS,984人)和休斯顿卫理公会医院(HMH,806人)中,利用深度学习模型从经胸超声心动图视频(AI-Echo)和心电图图像(AI-ECG)生成ATTR-CM概率。结果显示AI概率在诊断前3年即出现病例与对照的分离,双阴性筛查(阈值0.05)敏感性达90.9%和85.7%,双阳性筛查特异性达85.5%和88.9%。

要点

  • AI-ECG和AI-Echo可在ATTR-CM诊断前3年识别病例与对照的概率分离。
  • 双阴性筛查(阈值0.05)敏感性高,有助于排除临床前ATTR-CM。
  • 双阳性筛查特异性高,可用于风险分层和进一步影像确认。

核心结论

  • AI赋能的超声心动图和心电图可能实现ATTR-CM临床前病程中的可扩展风险分层。

研究设计与样本

  • 回顾性分析YNHHS内部队列984人和HMH外部队列806人,均为转诊接受核素心脏淀粉样变检测的个体。
  • 深度学习模型在经胸超声心动图视频(AI-Echo)和心电图图像(AI-ECG)上训练以区分ATTR-CM与年龄/性别匹配对照,生成研究级ATTR-CM概率(0%-100%)。

主要发现

  • YNHHS队列中位年龄74岁、女性44.3%,112人(11.4%)ATTR-CM检测阳性;HMH队列中位年龄69岁、女性34.5%,174人(21.6%)阳性。
  • 在核素检测前1至3年同时有AI-Echo和AI-ECG概率的个体中(YNHHS n=433,HMH n=174),双阴性筛查(阈值0.05)敏感性分别为90.9%和85.7%(特异性40.3%和41.2%)。
  • 双阳性筛查特异性分别为85.5%和88.9%(敏感性60.6%和42.9%)。

关键数值与推荐

  • AI-Echo和AI-ECG模型输出研究级ATTR-CM概率(0%-100%)。
  • 双阴性筛查阈值定义为0.05,双阳性筛查同样基于0.05阈值。

临床怎么用

  • AI-ECG和AI-Echo可作为ATTR-CM临床前风险分层的可扩展工具,双阴性筛查有助于排除,双阳性筛查提示需进一步影像确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) requires advanced imaging, precluding large-scale preclinical testing. Artificial intelligence (AI)-enabled transthoracic echocardiography (TTE) and electrocardiography (ECG) may provide a scalable strategy for preclinical monitoring. METHODS: This was a retrospective analysis of individuals referred for nuclear cardiac amyloid testing at the Yale-New Haven Health System (YNHHS, internal cohort) and Houston Methodist Hospitals (HMH, external cohort). Deep learning models trained to discriminate ATTR-CM from age/sex-matched controls on TTE videos (AI-Echo) and ECG images (AI-ECG) were deployed to generate study-level ATTR-CM probabilities (0%-100%). Longitudinal trends in AI-derived probabilities were examined using age/sex-adjusted linear mixed models, and their discrimination of future disease was evaluated across preclinical stages. RESULTS: Among 984 participants at YNHHS (median age 74 years, 44.3% female) and 806 at HMH (median age 69 years, 34.5% female), 112 (11.4%) and 174 (21.6%) tested positive for ATTR-CM, respectively. Across cohorts and modalities, AI-derived ATTR-CM probabilities from 7352 TTEs and 32 205 ECGs diverged as early as 3 years before diagnosis in cases vs controls (ptime(x)group interaction ≤ .004). Among those with both AI-Echo and AI-ECG probabilities available 1 to 3 years before nuclear testing [n = 433 (YNHHS) sand 174 (HMH)], a double-negative screen at a 0.05 threshold [164 (37.9%) and 66 (37.9%), vs all else] had 90.9% and 85.7% sensitivity (specificity of 40.3% and 41.2%), whereas a double-positive screen [78 (18.0%) and 26 (14.9%), vs all else] had 85.5% and 88.9% specificity (sensitivity of 60.6% and 42.9%). CONCLUSIONS: Artificial intelligence-enabled echocardiography and electrocardiography may enable scalable risk stratification of ATTR-CM during its preclinical course.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Oikonomou EK, Sangha V, Shankar SV, et al. Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy. Eur Heart J. 2025. PMID: 40679604. doi:10.1093/eurheartj/ehaf450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。